earticle

영어

Recombinant antibody proteins can be applied to treat many various cancers. They are primarily produced using mammalian, insect, and bacteria cell culture systems. However, plant expression systems have been currently developed to produce antibodies. In particular, production of recombinant therapeutic antibodies using plant expression systems have several advantages, which are lack of human pathogenic agents, efficient production cost, and easy large scale up. In this study, we generated transgenic Nicotiana tabacum plant expressing both anti-colorectal cancer large single chain (LSC) CO17-1AK and anti-human epidermal growth factor receptor 2 (HER2) VHH-FcK monoclonal antibodies (mAbs) by cross-pollinating with plants expressing LSC CO17-1AK and anti-HER2 VHH-FcK, respectively. Plants expressing both LSC CO17-1AK and anti-HER2 VHH-FcK were screened with polymerase chain reaction and Western blot analyses. Enzyme-linked immunosorbent assay (ELISA) confirmed the binding of the LSC CO17-1AK and anti-HER2 VHH-FcK to the HER2 and the GA733 proteins, respectively. The result of this study indicated that both mAb LSC CO17-1AK and anti-HER2 VHH-FcK produced in plant have their specific binding activities against HER2 and the GA733 antigens similar to their parental antibodies, respectively.